EDITAS MEDICINE, INC. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
EDITAS MEDICINE, INC. (EDIT) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $75.50 million as of 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2021-02-26
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $75.50M.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $75.40M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2020-12-31 | $75.50M 10-K · filed 2021-02-26 |
| 2019-12-31 | $75.40M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |